Presence of Metallic Fe Nanoclusters in r-(Al,Fe)2O3 Solid Solutions

Powders of R-(Al1-xFex)2O3 solid solutions prepared by the calcination in air of the corresponding γ-(Al1- xFex)2O3 powders were studied by several techniques including X-ray diffraction, field-emission-gun scanning electron microscopy, transmission Mössbauer spectroscopy, integral low-energy electron Mössbauer spectroscopy (ILEEMS), and Fe K-edge X-ray absorption near-edge structure (XANES) measurements. The asymmetry of the characteristic Mo¨ssbauer doublet representing Fe3+ ions substituting for Al3+ ions in the corundum lattice of R-(Al1-xFex)2O3 solid solutions was resolved and explained for the first time by using two additional subspectra, i.e., a broad second doublet characteristic of a very distorted octahedral site for Fe3+ and a singlet attributable to R-Fe, suggesting the presence of metallic iron nanoclusters consisting of only a few number of atoms within the solid solution grains. ILEEMS studies showed that the Fe nanoclusters are evenly distributed among the surface layers and the cores of the grains. Fe K-edge XANES measurements further confirmed the occurrence of metallic iron. The proportion of Fe nanoclusters increases when the total iron content is decreased, as does the proportion of distorted octahedral site, suggesting that they are located around the iron nanoclusters. The formation of the metallic Fe nanoclusters in the R-(Al1-xFex)2O3 grains is thought to be a consequence of the γ f R phase transition which implies structural rearrangement on both the cationic and anionic sublattices

Selective phosphodiesterase inhibitors: a promising target for cognition enhancement

# The Author(s) 2008. This article is published with open access at Springerlink.com Rationale One of the major complaints most people face during aging is an impairment in cognitive functioning. This has a negative impact on the quality of daily life and is even more prominent in patients suffering from neurodegenerative and psychiatric disorders including Alzheimer’s disease, schizophrenia, and depression. So far, the majority of cognition enhancers are generally targeting one particular neurotransmitter system. However, recently phosphodiesterases (PDEs) have gained increased attention as a potential new target for cognition enhancement. Inhibition of PDEs increases the intracellular availability of the second messengers cGMP and/or cAMP. Objective The aim of this review was to provide an overvie

Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.

Background: Data on durability of first-line antiretroviral therapy (ART) in children with human immunodeficiency virus (HIV) are limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand. Methods: Children aged <18 years initiating combination ART (≥2 nucleoside reverse transcriptase inhibitors [NRTIs] plus nonnucleoside reverse transcriptase inhibitor [NNRTI] or boosted protease inhibitor [PI]) were included. Switch to second-line was defined as (i) change across drug class (PI to NNRTI or vice versa) or within PI class plus change of ≥1 NRTI; (ii) change from single to dual PI; or (iii) addition of a new drug class. Cumulative incidence of switch was calculated with death and loss to follow-up as competing risks. Results: Of 3668 children included, median age at ART initiation was 6.1 (interquartile range (IQR), 1.7-10.5) years. Initial regimens were 32% PI based, 34% nevirapine (NVP) based, and 33% efavirenz based. Median duration of follow-up was 5.4 (IQR, 2.9-8.3) years. Cumulative incidence of switch at 5 years was 21% (95% confidence interval, 20%-23%), with significant regional variations. Median time to switch was 30 (IQR, 16-58) months; two-thirds of switches were related to treatment failure. In multivariable analysis, older age, severe immunosuppression and higher viral load (VL) at ART start, and NVP-based initial regimens were associated with increased risk of switch. Conclusions: One in 5 children switched to a second-line regimen by 5 years of ART, with two-thirds failure related. Advanced HIV, older age, and NVP-based regimens were associated with increased risk of switch